WO2007022459A3 - Processes and intermediates - Google Patents

Processes and intermediates Download PDF

Info

Publication number
WO2007022459A3
WO2007022459A3 PCT/US2006/032481 US2006032481W WO2007022459A3 WO 2007022459 A3 WO2007022459 A3 WO 2007022459A3 US 2006032481 W US2006032481 W US 2006032481W WO 2007022459 A3 WO2007022459 A3 WO 2007022459A3
Authority
WO
WIPO (PCT)
Prior art keywords
processes
intermediates
protease inhibitors
useful
compounds
Prior art date
Application number
PCT/US2006/032481
Other languages
French (fr)
Other versions
WO2007022459A2 (en
Inventor
Gerald J Tanoury
Minzhang Chen
John E Cochran
Original Assignee
Vertex Pharma
Gerald J Tanoury
Minzhang Chen
John E Cochran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2006279357A priority Critical patent/AU2006279357B2/en
Priority to DE602006013492T priority patent/DE602006013492D1/en
Priority to CA002619659A priority patent/CA2619659A1/en
Priority to PL06813568T priority patent/PL1934179T4/en
Priority to KR1020137024964A priority patent/KR20130110236A/en
Priority to NZ566049A priority patent/NZ566049A/en
Priority to DK06813568.0T priority patent/DK1934179T3/en
Priority to EP06813568A priority patent/EP1934179B1/en
Priority to KR1020147013418A priority patent/KR20140069370A/en
Priority to NZ593214A priority patent/NZ593214A/en
Priority to CN2006800384541A priority patent/CN101291909B/en
Priority to JP2008527189A priority patent/JP5203203B2/en
Priority to AT06813568T priority patent/ATE463480T1/en
Priority to BRPI0615029-2A priority patent/BRPI0615029A2/en
Application filed by Vertex Pharma, Gerald J Tanoury, Minzhang Chen, John E Cochran filed Critical Vertex Pharma
Priority to KR1020137005426A priority patent/KR20130038947A/en
Priority to SI200630710T priority patent/SI1934179T1/en
Publication of WO2007022459A2 publication Critical patent/WO2007022459A2/en
Priority to IL189585A priority patent/IL189585A/en
Priority to ZA200801791A priority patent/ZA200801791B/en
Publication of WO2007022459A3 publication Critical patent/WO2007022459A3/en
Priority to KR1020087006558A priority patent/KR101474405B1/en
Priority to HK08113896.0A priority patent/HK1122801A1/en
Priority to IL228770A priority patent/IL228770A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.
PCT/US2006/032481 2005-08-19 2006-08-18 Processes and intermediates WO2007022459A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SI200630710T SI1934179T1 (en) 2005-08-19 2006-08-18 Processes and intermediates
CA002619659A CA2619659A1 (en) 2005-08-19 2006-08-18 Processes and intermediates
PL06813568T PL1934179T4 (en) 2005-08-19 2006-08-18 Processes and intermediates
KR1020137024964A KR20130110236A (en) 2005-08-19 2006-08-18 Processes and intermediates
NZ566049A NZ566049A (en) 2005-08-19 2006-08-18 Processes and intermediates
DK06813568.0T DK1934179T3 (en) 2005-08-19 2006-08-18 Methods and intermediates
EP06813568A EP1934179B1 (en) 2005-08-19 2006-08-18 Processes and intermediates
KR1020147013418A KR20140069370A (en) 2005-08-19 2006-08-18 Processes and intermediates
NZ593214A NZ593214A (en) 2005-08-19 2006-08-18 Compounds and Processes for preparing serine protease inhibitors
CN2006800384541A CN101291909B (en) 2005-08-19 2006-08-18 Processes and intermediates
JP2008527189A JP5203203B2 (en) 2005-08-19 2006-08-18 Manufacturing processes and intermediates
AU2006279357A AU2006279357B2 (en) 2005-08-19 2006-08-18 Processes and intermediates
BRPI0615029-2A BRPI0615029A2 (en) 2005-08-19 2006-08-18 processes and intermediaries
AT06813568T ATE463480T1 (en) 2005-08-19 2006-08-18 PROCESS AND INTERMEDIATE PRODUCTS
KR1020137005426A KR20130038947A (en) 2005-08-19 2006-08-18 Processes and intermediates
DE602006013492T DE602006013492D1 (en) 2005-08-19 2006-08-18 PROCEDURE AND INTERMEDIATE PRODUCTS
IL189585A IL189585A (en) 2005-08-19 2008-02-18 Processes for the preparation of protease inhibitors and intermediates made by such processes
ZA200801791A ZA200801791B (en) 2005-08-19 2008-02-25 Processes and intermediates
KR1020087006558A KR101474405B1 (en) 2005-08-19 2008-03-18 Processes and intermediates
HK08113896.0A HK1122801A1 (en) 2005-08-19 2008-12-23 Processes and intermediates
IL228770A IL228770A0 (en) 2005-08-19 2013-10-07 Processes and intermaediates

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70996405P 2005-08-19 2005-08-19
US60/709,964 2005-08-19
US81004206P 2006-06-01 2006-06-01
US60/810,042 2006-06-01

Publications (2)

Publication Number Publication Date
WO2007022459A2 WO2007022459A2 (en) 2007-02-22
WO2007022459A3 true WO2007022459A3 (en) 2008-02-28

Family

ID=37708299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/032481 WO2007022459A2 (en) 2005-08-19 2006-08-18 Processes and intermediates

Country Status (25)

Country Link
US (3) US7776887B2 (en)
EP (4) EP2357170A1 (en)
JP (1) JP5203203B2 (en)
KR (4) KR20140069370A (en)
CN (2) CN101291909B (en)
AR (1) AR058025A1 (en)
AT (1) ATE463480T1 (en)
AU (1) AU2006279357B2 (en)
BR (1) BRPI0615029A2 (en)
CA (1) CA2619659A1 (en)
CY (2) CY1110214T1 (en)
DE (1) DE602006013492D1 (en)
DK (2) DK2194043T3 (en)
ES (2) ES2449268T3 (en)
HK (2) HK1122801A1 (en)
IL (2) IL189585A (en)
NZ (3) NZ593214A (en)
PL (3) PL385229A1 (en)
PT (2) PT2194043E (en)
RU (2) RU2446171C2 (en)
SG (1) SG2014013338A (en)
SI (2) SI1934179T1 (en)
TW (2) TW201245149A (en)
WO (1) WO2007022459A2 (en)
ZA (1) ZA200801791B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335276A (en) * 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
SV2003000617A (en) * 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
MY148123A (en) * 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2007016589A2 (en) * 2005-08-02 2007-02-08 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
JP5203203B2 (en) 2005-08-19 2013-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド Manufacturing processes and intermediates
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (en) * 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CN102614490A (en) 2006-02-27 2012-08-01 弗特克斯药品有限公司 Co-crystals having VX-950 and pharmaceutical compositions comprising the same
CA2646123A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Processes and intermediates for preparing steric compounds
EP2194039A1 (en) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
CA2672268A1 (en) * 2006-12-15 2008-06-26 Schering Corporation Bisulfite purification of an alpha-keto amide
WO2008106151A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP2134717A2 (en) * 2007-02-27 2009-12-23 Vertex Pharmceuticals Incorporated Inhibitors of serine proteases
CL2008002549A1 (en) * 2007-08-30 2010-09-03 Vertex Pharma Cocrystal comprising vx-950 and a cocrystal former selected from 3-methoxy-4-hydroxybenzoic acid, 2,4-dihydroxybenzoic acid and 2,5-dihydroxybenzoic acid; Preparation method; Pharmaceutical composition comprising cocrystal, useful as an antiviral agent in the treatment of hcv.
WO2009114633A1 (en) * 2008-03-12 2009-09-17 Virobay, Inc. Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
US8143448B2 (en) 2008-06-13 2012-03-27 Virobay, Inc. Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives
CA2728226A1 (en) 2008-06-24 2010-01-21 Codexis, Inc. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
EP2539320A1 (en) * 2010-02-25 2013-01-02 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg A process for the preparation of substituted prolyl peptides and similar peptidomimetics
WO2011153423A2 (en) 2010-06-03 2011-12-08 Vertex Pharmaceuticals Incorporated Processes and intermediates
CN102167680B (en) * 2011-03-23 2014-07-02 合亚医药科技（上海）有限公司 Preparation method of octahydrocyclopenta[c]pyrrole carboxylic acid derivative
EP2707347A1 (en) 2011-05-13 2014-03-19 Vertex Pharmaceuticals Inc. Processes and intermediates
WO2012158515A1 (en) * 2011-05-13 2012-11-22 Vertex Phamaceuticals Incorporated Process for the preparation of protease inhibitors
JP2013010738A (en) * 2011-05-31 2013-01-17 Sumitomo Chemical Co Ltd Method for producing ester compound
DE112012003457T5 (en) 2011-10-21 2015-03-12 Abbvie Inc. Combination treatment (e.g., with ABT-072 or ABT-333 from DAAs for use in the treatment of HCV)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2527510T1 (en) 2011-10-21 2015-01-26 Abbvie Inc. Methods for the treatment of HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
CN103183632A (en) * 2011-12-29 2013-07-03 山东方明药业集团股份有限公司 Purification method of 3-azabicyclo-octane hydrochloride
ITMI20120192A1 (en) 2012-02-13 2013-08-14 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF AN INHIBITOR OF VIRAL AND INTERMEDIATE PROTEASIS
ITMI20120359A1 (en) 2012-03-07 2013-09-08 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF USEFUL INTERMEDIATES IN THE PREPARATION OF A VIRAL PROTEASIS INHIBITOR
ITMI20121668A1 (en) * 2012-10-05 2014-04-06 Dipharma Francis Srl SUMMARY OF AN INTERMEDIATE OF AN ANTIVIRAL COMPOUND
ITMI20120391A1 (en) * 2012-03-13 2013-09-14 Dipharma Francis Srl PROCEDURE FOR THE SYNTHESIS OF A USEFUL CYCLOPROPYLAMID INTERMEDIATE IN THE PREPARATION OF A VIRAL PROTEASIS INHIBITOR
WO2013136265A1 (en) 2012-03-13 2013-09-19 Dipharma Francis S.R.L. Synthesis of an intermediate of an antiviral compound
US20150038677A1 (en) 2012-03-16 2015-02-05 Sandoz Ag Process for the synthesis of telaprevir, or pharmaceutically acceptable salts or solvates as well as intermediate products thereof
ITMI20120608A1 (en) 2012-04-13 2013-10-14 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF AN INHIBITOR OF VIRAL PROTEASES IN AMORPHOUS FORM
ITMI20120800A1 (en) * 2012-05-10 2013-11-11 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF A USEFUL INTERMEDIATE IN THE PREPARATION OF A VIRAL PROTEASIS INHIBITOR
CN103450066B (en) * 2012-05-30 2017-03-15 博瑞生物医药（苏州）股份有限公司 The preparation method of Telaprevir intermediate
AR091192A1 (en) 2012-05-30 2015-01-21 Chemo Iberica Sa MULTICOMPONENT PROCEDURE FOR THE PREPARATION OF BICYCLE COMPOUNDS
ITMI20120990A1 (en) * 2012-06-07 2013-12-08 Dipharma Francis Srl SYNTHESIS OF A VIRAL PROTEASIS INHIBITOR
CN104470914A (en) * 2012-06-20 2015-03-25 桑多斯股份公司 Synthesis of telaprevir and boceprevir, or pharmaceutically acceptable salts or solvates as well as intermediate products thereof including -amino acids prepared via mukaiyama aldol addition
WO2013189978A1 (en) 2012-06-20 2013-12-27 Sandoz Ag PROCESS FOR PREPARING ß-AMINO ACID DERIVATIVES AND USE OF SAID PROCESS FOR PREPARING TELAPREVIR
WO2014019179A1 (en) * 2012-08-01 2014-02-06 上海迪赛诺药业有限公司 Method for preparing telaprevir and intermediate thereof
WO2014033667A1 (en) 2012-08-30 2014-03-06 Ranbaxy Laboratories Limited Process for the preparation of telaprevir
CN102875648B (en) * 2012-09-26 2014-02-19 深圳翰宇药业股份有限公司 Method for preparing telaprevir
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
ITMI20122036A1 (en) * 2012-11-29 2014-05-30 Dipharma Francis Srl SUMMARY OF AN INTERMEDIATE OF AN ANTIVIRAL COMPOUND
US20160039871A1 (en) * 2012-12-21 2016-02-11 Sandoz Ag Novel forms of telaprevir
WO2014096374A1 (en) 2012-12-21 2014-06-26 Sandoz Ag Process for the synthesis of pyrrolidines and pyrroles
CN103936651B (en) * 2013-01-18 2016-06-22 上海医药工业研究院 Intermediate III of anti-hepatitis C medicine Boceprevir and its preparation method and application
ITMI20130706A1 (en) * 2013-04-30 2014-10-31 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF AN INHIBITOR OF VIRAL AND INTERMEDIATE PROTEASIS
CN103288671B (en) * 2013-06-20 2014-10-29 上海步越化工科技有限公司 Synthetic method of (3S)-3-amino-N-cyclopropyl-2-hydroxyhexanamide hydrochloride
WO2014203224A1 (en) 2013-06-21 2014-12-24 Ranbaxy Laboratories Limited Process for the preparation of telaprevir and its intermediates
WO2014203208A1 (en) 2013-06-21 2014-12-24 Ranbaxy Laboratories Limited Process for the preparation of telaprevir and intermediates thereof
CN104292146B (en) * 2013-06-24 2017-04-26 上海医药工业研究院 Telaprevir intermediate and preparation method thereof
CN103342656B (en) * 2013-07-04 2015-04-08 苏州永健生物医药有限公司 Synthesis method of Telaprevir intermediate
CN103435532B (en) * 2013-09-02 2015-07-08 苏州永健生物医药有限公司 Synthetic method of boceprevir intermediate
WO2015036522A1 (en) * 2013-09-13 2015-03-19 Sandoz Ag Process for the preparation and isolation of (s)-3-amino-n-cyclopropyl-2,2-dialkoxyhexanamide and (s)-tert-butyl(1-(cyclopropylamino)-2,2-dialkoxy-1-oxohexan-3-yl)carbamate and use thereof for the preparation of telaprevir
JP2016539931A (en) 2013-10-23 2016-12-22 株式会社カネカ Tetrapeptide compound and method for producing the same
CN103664739B (en) * 2013-12-10 2016-04-27 湖南科源生物制品有限公司 A kind of preparation method of Telaprevir intermediate
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN105646329A (en) * 2014-11-28 2016-06-08 重庆圣华曦药业股份有限公司 Method for preparing telaprevir intermediate
CN105111129A (en) * 2015-08-24 2015-12-02 上海合全药业股份有限公司 Preparation method of (1S, 3aR, 6aS)-octahydro cyclopenta [C] pyrrole-1-carboxylic acid tert-butyl ester oxalate
CN105601556B (en) * 2015-12-02 2018-11-13 镇江市高等专科学校 The preparation method of telavi bicyclic pyrrole alkane intermediate
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP3891508A1 (en) 2018-12-04 2021-10-13 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
KR20230038457A (en) 2020-06-10 2023-03-20 알리고스 테라퓨틱스 인코포레이티드 Antiviral compounds for treating coronavirus, picornavirus and norovirus infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3211676A1 (en) * 1982-03-30 1983-10-06 Hoechst Ag NEW DERIVATIVES OF CYCLOALKA (C) PYRROL CARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF AND NEW CYCLOALKA (C) PYRROL CARBONIC ACIDS AS THE INTERMEDIATE LEVELS AND METHODS
US5468858A (en) * 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
WO2002018369A2 (en) * 2000-08-31 2002-03-07 Eli Lilly And Company Peptidomimetic protease inhibitors
US20050197301A1 (en) * 2004-02-27 2005-09-08 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967344A (en) * 1995-09-05 1997-03-11 Koei Chem Co Ltd Production of optically active n-benzyloxycarbonylpipecolic acid
EP0907659A1 (en) 1996-05-10 1999-04-14 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
JP3863230B2 (en) 1996-08-16 2006-12-27 株式会社カネカ Process for producing β-amino-α-hydroxy acid derivative
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
ES2234144T3 (en) 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. ANALOGS OF INHIBITING PEPTIDES OF HEPATITIS C.
IT1299134B1 (en) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio PROCEDURE FOR THE PRODUCTION OF PEPTIDES WITH PROTEAS INHIBITING THE NS3 PROTEASIS OF THE HCV VIRUS, PEPTIDES SO OBTAINABLE AND PEPTIDES
AU3376699A (en) 1998-03-31 1999-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (en) 1998-08-12 2000-02-17 Univ Stuttgart Modification of engineering polymers with N-basic groups and ion exchange groups in the side chain gives membranes of good thermal and mechanical stability useful for fuel cells, diffusion dialysis, electrodialysis, and reverse osmosis
GB9825946D0 (en) 1998-11-26 1999-01-20 Angeletti P Ist Richerche Bio Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
GB2363605B (en) 1999-03-12 2004-02-04 Ajinomoto Kk Process for the preparation of alpha-aminoketone derivatives
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
CA2376961A1 (en) 1999-07-26 2001-02-01 Bristol-Myers Squibb Pharma Company Lactam inhibitors of hepatitis c virus ns3 protease
US6699855B2 (en) 2000-02-29 2004-03-02 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
JP4806154B2 (en) 2000-04-03 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitors of serine proteases, especially hepatitis C virus NS3 protease
SK14192002A3 (en) 2000-04-05 2003-03-04 Schering Corporation Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic p2 moieties
US6914122B2 (en) 2000-04-19 2005-07-05 Schering Corporation Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
AR029851A1 (en) 2000-07-21 2003-07-16 Dendreon Corp NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C
PL206255B1 (en) 2000-07-21 2010-07-30 Dendreon Corporationdendreon Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR034127A1 (en) 2000-07-21 2004-02-04 Schering Corp IMIDAZOLIDINONES AS INHIBITORS OF NS3-SERINA PROTEASA OF THE HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THEIR PREPARATION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
HUP0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
ES2263687T3 (en) 2000-11-20 2006-12-16 Bristol-Myers Squibb Company TRIPEPTIDIC INHIBITORS OF HEPATITIS C.
AU2002230764A1 (en) 2000-12-13 2002-06-24 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
IL159087A0 (en) 2001-07-11 2004-05-12 Vertex Pharma Bridged bicyclic compounds and pharmaceutical compositions containing the same
AU2002348414B2 (en) * 2001-10-24 2009-10-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
WO2004072243A2 (en) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
EP1613620A1 (en) 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CA2540031A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
JP5203203B2 (en) 2005-08-19 2013-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド Manufacturing processes and intermediates
NZ580917A (en) 2007-05-04 2012-06-29 Vertex Pharma Combinations of protease inhibitors such as VX-950 and polymerase inhibitors for the treatment of HCV infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3211676A1 (en) * 1982-03-30 1983-10-06 Hoechst Ag NEW DERIVATIVES OF CYCLOALKA (C) PYRROL CARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF AND NEW CYCLOALKA (C) PYRROL CARBONIC ACIDS AS THE INTERMEDIATE LEVELS AND METHODS
US5468858A (en) * 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
WO2002018369A2 (en) * 2000-08-31 2002-03-07 Eli Lilly And Company Peptidomimetic protease inhibitors
US20050197301A1 (en) * 2004-02-27 2005-09-08 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BERGMEIER S C ET AL: "Synthesis of Bicyclic Proline Analogs Using a Formal [3 + 2] Intramolecular Aziridine-Allylsilane Cycloaddition Reaction", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 55, no. 26, 25 June 1999 (1999-06-25), pages 8025 - 8038, XP004168571, ISSN: 0040-4020 *
CHEN S-H ET AL: "Synthesis and evaluation of tripeptidyl [alpha]-ketoamides as human rhinovirus 3C protease inhibitors", 20 October 2003, BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS 20 OCT 2003 UNITED KINGDOM, VOL. 13, NR. 20, PAGE(S) 3531-3536, ISSN: 0960-894X, XP002461430 *
ESCH P M ET AL: "Reductive Cyclization of Carbon-Centered Glycine Radicals", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 48, no. 22, 1992, pages 4659 - 4676, XP001061646, ISSN: 0040-4020 *
GARRISON GREGORY L ET AL: "Novel 3,7-diheterabicyclo(3.3.1)nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-(4-(1H-imidazol-1-yl- benzoyl)-7-isopropyl-3,7-diazabicyclo(3.3.1)nonane dihydroperchlorate", 1996, JOURNAL OF MEDICINAL CHEMISTRY, VOL. 39, NR. 13, PAGE(S) 2559-2570, ISSN: 0022-2623, XP002461432 *
LAMAR JASON ET AL: "Novel P4 truncated tripeptidyl alpha-ketoamides as HCV protease inhibitors.", 5 January 2004, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, VOL. 14, NR. 1, PAGE(S) 263-266, ISSN: 0960-894X, XP002461431 *
MONN JAMES A: "A concise, stereocontrolled thiazolium ylide approach to kainic acid", 1994, JOURNAL OF ORGANIC CHEMISTRY, VOL. 59, NR. 10, PAGE(S) 2773-2778, ISSN: 0022-3263, XP002419726 *
TOOM L ET AL: "Microwave-assisted Raney nickel reduction of bispidinone thioketals to N,N'-dialkylbispidines", SYNTHESIS 14 JUN 2006 GERMANY, no. 12, 14 June 2006 (2006-06-14), pages 2064 - 2068, XP002461429, ISSN: 0039-7881 *
YIP Y ET AL: "P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 14, no. 19, 4 October 2004 (2004-10-04), pages 5007 - 5011, XP004548807, ISSN: 0960-894X *
YIP, YVONNE ET AL: "Discovery of a novel bicycloproline P2 bearing peptidyl .alpha.-ketoamide LY514962 as HCV protease inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 14(1), 251-256 CODEN: BMCLE8; ISSN: 0960-894X, 2004, XP002419660 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Also Published As

Publication number Publication date
AU2006279357A1 (en) 2007-02-22
AU2006279357B2 (en) 2012-05-31
WO2007022459A2 (en) 2007-02-22
PL1934179T4 (en) 2014-03-31
CN102382170A (en) 2012-03-21
EP1934179B1 (en) 2010-04-07
KR20140069370A (en) 2014-06-09
CY1114916T1 (en) 2016-12-14
ZA200801791B (en) 2008-12-31
ES2344156T3 (en) 2010-08-19
KR20130038947A (en) 2013-04-18
ES2449268T3 (en) 2014-03-19
PL1934179T3 (en) 2010-09-30
NZ593214A (en) 2013-02-22
EP2194043A3 (en) 2010-11-24
DK2194043T3 (en) 2014-01-20
EP2194043B1 (en) 2013-12-25
CY1110214T1 (en) 2015-01-14
TW200800889A (en) 2008-01-01
TW201245149A (en) 2012-11-16
EP2357170A1 (en) 2011-08-17
CN101291909B (en) 2012-09-05
HK1122801A1 (en) 2009-05-29
US20100174077A1 (en) 2010-07-08
ATE463480T1 (en) 2010-04-15
CA2619659A1 (en) 2007-02-22
NZ604087A (en) 2014-07-25
EP2194043A2 (en) 2010-06-09
EP2364970A1 (en) 2011-09-14
IL189585A0 (en) 2008-08-07
JP5203203B2 (en) 2013-06-05
RU2011148615A (en) 2013-06-10
IL228770A0 (en) 2013-12-31
PT2194043E (en) 2014-03-04
HK1145022A1 (en) 2011-03-25
JP2009504780A (en) 2009-02-05
DK1934179T3 (en) 2010-08-09
US20070087973A1 (en) 2007-04-19
RU2008110479A (en) 2009-09-27
US8637457B2 (en) 2014-01-28
US20140107318A1 (en) 2014-04-17
PL2194043T3 (en) 2014-07-31
SG2014013338A (en) 2014-06-27
PL385229A1 (en) 2008-09-29
KR20080047396A (en) 2008-05-28
SI1934179T1 (en) 2010-08-31
SI2194043T1 (en) 2014-04-30
IL189585A (en) 2013-10-31
KR101474405B1 (en) 2014-12-23
AR058025A1 (en) 2008-01-23
NZ566049A (en) 2011-07-29
CN101291909A (en) 2008-10-22
PT1934179E (en) 2010-07-12
TWI391376B (en) 2013-04-01
KR20130110236A (en) 2013-10-08
EP1934179A2 (en) 2008-06-25
BRPI0615029A2 (en) 2009-06-16
DE602006013492D1 (en) 2010-05-20
RU2446171C2 (en) 2012-03-27
US7776887B2 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
WO2007022459A3 (en) Processes and intermediates
EP1924593B8 (en) Hcv ns3 protease inhibitors
WO2009082701A8 (en) Hcv protease inhibitors and uses thereof
WO2006119061A3 (en) Hcv ns3 protease inhibitors
AP2009004971A0 (en) Inhibitors of serine proteases for the treatment of HCV infections
MX2011011272A (en) Processes and intermediates.
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
WO2005087731A8 (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2008057995A3 (en) Hcv protease inhibitors
WO2005087725A3 (en) Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087721A3 (en) Compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2008051477A3 (en) Hcv ns3 protease inhibitors
WO2007025307A3 (en) Inhibitors of serine proteases
WO2011002808A8 (en) Hcv protease inhibitors and uses thereof
MX2010006736A (en) Hcv protease inhibitors and uses thereof.
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
WO2008124148A3 (en) Sulfur compounds as inhiibitors of hepatitis c virus ns3 serine protease
IL187453A0 (en) The preparation and uses of compounds as aspartyl protease inhibitors
WO2006047528A3 (en) Pyrazolobenzamides and derivatives as factor xa inhibitors
WO2007079199A3 (en) Substituted bis-amide metalloprotease inhibitors
WO2007009109A3 (en) Antiviral compounds
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
WO2008133734A3 (en) Method and compositions for treating hiv infections

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680038454.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 189585

Country of ref document: IL

Ref document number: MX/a/2008/002322

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2619659

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 566049

Country of ref document: NZ

Ref document number: 2008527189

Country of ref document: JP

Ref document number: 738/KOLNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006279357

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006813568

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087006558

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008110479

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006279357

Country of ref document: AU

Date of ref document: 20060818

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06813568

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0615029

Country of ref document: BR

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1020137005426

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020137024964

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020147013418

Country of ref document: KR